E3 PreliminaryPreliminaryPEM not requiredMechanisticPeer-reviewedMachine draft
Role of Lactobacillus acidophilus loaded floating beads in chronic fatigue syndrome: behavioral and biochemical evidences.
Singh, P K, Chopra, K, Kuhad, A et al. · Neurogastroenterology and motility · 2012 · DOI
Quick Summary
This study tested whether a beneficial bacteria called Lactobacillus acidophilus could help reduce fatigue symptoms in rats. Researchers created extreme fatigue in rats through repeated exhausting swimming, then gave some rats either the bacteria alone or the bacteria packaged in special beads designed to survive digestion. The bacteria treatment reduced fatigue-like behavior and improved markers of inflammation and immune system stress.
Why It Matters
This study explores the gut-brain axis as a potential mechanism in CFS pathogenesis and suggests probiotics as a possible therapeutic avenue. For ME/CFS patients, understanding whether microbiota interventions can reduce inflammatory markers and fatigue symptoms could open new treatment options, especially if findings translate to human studies.
Observed Findings
- Forced swim testing increased immobility time from 32±7 s to 665±22 s and post-swim fatigue time from 22±2 s to 196±6 s by day 20, demonstrating severe fatigue-like behavior.
- LAB and LAB-loaded floating bead treatment significantly decreased immobility and post-swim fatigue times compared to controls (P<0.05).
- Untreated fatigued rats showed splenomegaly, thymic atrophy, elevated serum TNF-α, and increased oxido-nitrosative stress in brain tissue.
- LAB treatment restored spleen and thymus to normal size and significantly reduced TNF-α and oxidative stress markers.
Inferred Conclusions
- Lactobacillus acidophilus has therapeutic potential in attenuating fatigue-like behaviors and associated inflammatory/immune dysfunction.
- Encapsulation of LAB in alginate beads may improve therapeutic efficacy, possibly by protecting the bacteria during transit and enhancing targeted delivery.
Remaining Questions
- Does this rat fatigue model accurately represent the chronic multisystemic pathology of human ME/CFS, or are key mechanistic differences present?
- Would LAB treatment be effective in human CFS patients, and at what doses and treatment durations?
- Which specific microbial metabolites or pathways mediate the anti-fatigue and anti-inflammatory effects observed?
What This Study Does Not Prove
This animal model study does not prove that probiotics will work in humans with ME/CFS, nor does it establish that the fatigue induced in rats is truly equivalent to human CFS pathophysiology. The study correlates LAB administration with reduced fatigue markers but does not definitively prove that the bacteria mechanism is responsible for the improvement rather than other factors.
Tags
Symptom:Fatigue
Biomarker:CytokinesBlood Biomarker
Method Flag:PEM Not DefinedWeak Case DefinitionSmall SampleExploratory Only
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →